Aplidin will be re-evaluated by the EMA. The European Commission revokes the decision that initially denied PharmaMar's marketing authorisation for multiple myeloma due to a conflict of interest.


8 July 2024 - The European Commission has acknowledged that an expert from the Scientific Advisory Group, who was developing a rival product was allowed to participate in the marketing authorisation procedure for Aplidin (plitidepsin).

PharmaMar has received a notification from the European Commission informing the Company of its decision to revoke the refusal to grant marketing authorisation for Aplidin in multiple myeloma.

Read PharmaMar press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , Europe , Regulation , Dossier